Your browser doesn't support javascript.
loading
Pelvic bone marrow dose-volume predictors of late lymphopenia following pelvic lymph node radiation therapy for prostate cancer.
Pavarini, Maddalena; Alborghetti, Lisa; Aimonetto, Stefania; Maggio, Angelo; Landoni, Valeria; Ferrari, Paolo; Bianculli, Antonella; Petrucci, Edoardo; Cicchetti, Alessandro; Farina, Bruno; Ubeira-Gabellini, Maria Giulia; Salmoiraghi, Paolo; Moretti, Eugenia; Avuzzi, Barbara; Giandini, Tommaso; Munoz, Fernando; Magli, Alessandro; Sanguineti, Giuseppe; Magdalena Waskiewicz, Justyna; Rago, Luciana; Cante, Domenico; Girelli, Giuseppe; Vavassori, Vittorio; Di Muzio, Nadia Gisella; Rancati, Tiziana; Cozzarini, Cesare; Fiorino, Claudio.
Afiliação
  • Pavarini M; IRCCS San Raffaele Scientific Institute, Medical Physics Dept, Milano, Italy.
  • Alborghetti L; IRCCS San Raffaele Scientific Institute, Medical Physics Dept, Milano, Italy.
  • Aimonetto S; Ospedale Regionale Parini-AUSL Valle d'Aosta, Medical Physics Dept, Aosta, Italy.
  • Maggio A; Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia IRCCS, Medical Physics Dept, Candiolo, Italy.
  • Landoni V; IRCCS Istituto Nazionale Tumori Regina Elena, UOSD Laboratorio di Fisica Medica e Sistemi Esperti, Roma, Italy.
  • Ferrari P; Comprensorio Sanitario di Bolzano, Medical Physics Dept, Bolzano, Italy.
  • Bianculli A; IRCCS Crob, Medical Physics Dept, Rionero in Vulture, Italy.
  • Petrucci E; ASL TO4 Ospedale di Ivrea, Medical Physics Dept, Ivrea, Italy.
  • Cicchetti A; Fondazione IRCCS Istituto Nazionale dei Tumori, Unit of Data Science, Milano, Italy.
  • Farina B; Ospedale degli Infermi, Medical Physics Dept, Biella, Italy.
  • Ubeira-Gabellini MG; IRCCS San Raffaele Scientific Institute, Medical Physics Dept, Milano, Italy.
  • Salmoiraghi P; Cliniche Gavazzeni-Humanitas, Medical Physics Dept, Bergamo, Italy.
  • Moretti E; Azienda sanitaria universitaria Friuli Centrale, Medical Physics Department, Udine, Italy.
  • Avuzzi B; Fondazione IRCCS Istituto Nazionale dei Tumori, Radiotherapy Department, Milano, Italy.
  • Giandini T; Fondazione IRCCS Istituto Nazionale dei Tumori, Medical Physics Department, Milano, Italy.
  • Munoz F; Ospedale Regionale Parini-AUSL Valle d'Aosta, Department of Radiation Oncology, Aosta, Italy.
  • Magli A; Azienda Ospedaliero Universitaria S. Maria della Misericordia, Department of Radiotherapy, Udine, Italy.
  • Sanguineti G; IRCCS Regina Elena National Cancer Institute, Department of Radiation Oncology, Roma, Italy.
  • Magdalena Waskiewicz J; Comprensorio Sanitario di Bolzano, Radiotherapy, Bolzano, Italy.
  • Rago L; IRCCS Crob, Radiotherapy, Rionero in Vulture, Italy.
  • Cante D; ASL TO4 Ospedale di Ivrea, Radiotherapy, Ivrea, Italy.
  • Girelli G; Ospedale degli Infermi, Department of Radiotherapy, Biella, Italy.
  • Vavassori V; Cliniche Gavazzeni-Humanitas, Radiotherapy Dept, Bergamo, Italy.
  • Di Muzio NG; Vita-Salute San Raffaele University, Milano, Italy; IRCCS San Raffaele Scientific Institute, Department of Radiation Oncology, Milano, Italy.
  • Rancati T; Fondazione IRCCS Istituto Nazionale dei Tumori, Unit of Data Science, Milano, Italy.
  • Cozzarini C; IRCCS San Raffaele Scientific Institute, Department of Radiation Oncology, Milano, Italy.
  • Fiorino C; IRCCS San Raffaele Scientific Institute, Medical Physics Dept, Milano, Italy. Electronic address: fiorino.claudio@hsr.it.
Radiother Oncol ; 195: 110230, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38503355
ABSTRACT
BACKGROUND AND

PURPOSE:

Given the substantial lack of knowledge, we aimed to assess clinical/dosimetry predictors of late hematological toxicity on patients undergoing pelvic-nodes irradiation (PNI) for prostate cancer (PCa) within a prospective multi-institute study. MATERIALS AND

METHODS:

Clinical/dosimetry/blood test data were prospectively collected including lymphocytes count (ALC) at baseline, mid/end-PNI, 3/6 months and every 6 months up to 5-year after PNI. DVHs of the Body, ileum (BMILEUM), lumbosacral spine (BMLS), lower pelvis (BMPELVIS), and whole pelvis (BMTOT) were extracted. Current analysis focused on 2-year CTCAEv4.03 Grade ≥ 2 (G2+) lymphopenia (ALC < 800/µL). DVH parameters that better discriminate patients with/without toxicity were first identified. After data pre-processing to limit overfitting, a multi-variable logistic regression model combining DVH and clinical information was identified and internally validated by bootstrap.

RESULTS:

Complete data of 499 patients were available 46 patients (9.2 %) experienced late G2+ lymphopenia. DVH parameters of BMLS/BMPELVIS/BMTOT and Body were associated to increased G2+ lymphopenia. The variables retained in the resulting model were ALC at baseline [HR = 0.997, 95 %CI 0.996-0.998, p < 0.0001], smoke (yes/no) [HR = 2.9, 95 %CI 1.25-6.76, p = 0.013] and BMLS-V ≥ 24 Gy (cc) [HR = 1.006, 95 %CI 1.002-1.011, p = 0.003]. When acute G3+ lymphopenia (yes/no) was considered, it was retained in the model [HR = 4.517, 95 %CI 1.954-10.441, p = 0.0004]. Performances of the models were relatively high (AUC = 0.87/0.88) and confirmed by validation.

CONCLUSIONS:

Two-year lymphopenia after PNI for PCa is largely modulated by baseline ALC, with an independent role of acute G3+ lymphopenia. BMLS-V24 was the best dosimetry predictor constraints for BMTOT (V10Gy < 1520 cc, V20Gy < 1250 cc, V30Gy < 850 cc), and BMLS (V24y < 307 cc) were suggested to potentially reduce the risk.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Medula Óssea / Linfopenia Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Medula Óssea / Linfopenia Idioma: En Ano de publicação: 2024 Tipo de documento: Article